...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Drug Delivery and Therapeutics >A simple randomized comparative study to evaluate the efficacy of 0.7% w/v Olopatadine hydrochloride ophthalmic solution and the Fixed Dose Combination of 0.1% w/v Olopatadine hydrochloride and 0.4% w/v Ketorolac tromethamine ophthalmic solution for the
【24h】

A simple randomized comparative study to evaluate the efficacy of 0.7% w/v Olopatadine hydrochloride ophthalmic solution and the Fixed Dose Combination of 0.1% w/v Olopatadine hydrochloride and 0.4% w/v Ketorolac tromethamine ophthalmic solution for the

机译：一个简单的随机比较研究评估0.7％w / v盐酸奥洛他定滴眼液的疗效以及0.1％w / v盐酸奥洛他定和0.4％w / v酮咯酸氨丁三醇滴眼液的固定剂量组合

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Conjunctivitis is defined as the inflammation of the conjunctiva. Allergic conjunctivitis is an acute, intermittent or chronic inflammation of the conjunctiva due to air borne allergens. Allergic reactions occur when the immune system is hypersensitive to normally harmless environmental substances, called allergens. Allergic conjunctivitis is an increasingly prevalent allergic reaction and currently 40% of global population is suffering from allergic conjunctivitis. Being an immunopathological disease, Conjunctival mast cell degranulation plays a major role in ocular allergic disease and so treatment options should be concentrated on preventing degranulation or of antagonizing the effects of the primary mediator, histamine. Commonly used medications are: Topical OTC antihistamines (eg, ketotifen) , topical prescription antihistamines (eg, olopatadine, bepotastine, alcaftadine), NSAIDs (eg, ketorolac), or mast cell stabilizers (eg, nedocromil, cromolyn, azelastine) and can be used separately or in combination. In our study, the safety profile of Olopatadine 0.7% is comparable with fixed dose combination of Olopatadine 0.1% and ketorolac tromethamine 0.4% by assessing the reduction in the severity of four parameters (ocular itching, conjunctival hyperemia, chemosis and tearing) of allergic conjunctivitis over 14 days of daily treatment. Ours is a Prospective case observational study conducted from August 2018-January 2019. A total of 80 patients were screened from the ophthalmology outpatient department. All the subjects who fulfilled eligibility criteria were randomly assigned in equal proportions into two arms i.e, group-1(patients receiving 0.7% olopatidine Hcl eye drops) & group-2( patients receiving 0.1% olopatidine Hcl+ 0.4% ketorolac tromethamine eye drops.). It was observed that there was a significant difference in the percentage reduction of all the four parameters in the group 1 (i.e; patients treated with monotherapy) than the group 2 (i.e; patients treated with combination therapy). From this we concluded that monotherapy of 0.7% Olopatadine hydrochloride ophthalmic solution was found to be more effective in reducing the clinical signs and symptoms of allergic conjunctivitis than dual combination therapy of 0.1% Olopatadine hydrochloride + 0.4% Ketorolac tromethamine ophthalmic solution.
机译：结膜炎定义为结膜发炎。过敏性结膜炎是由于空气中的过敏原引起的结膜的急性，间歇性或慢性炎症。当免疫系统对通常被称为过敏原的正常无害环境物质过敏时，就会发生过敏反应。过敏性结膜炎是越来越普遍的过敏反应，目前全球40％的人口患有过敏性结膜炎。结膜肥大细胞脱粒是一种免疫病理性疾病，在眼部过敏性疾病中起主要作用，因此治疗选择应集中在防止脱粒或拮抗主要介质组胺的作用上。常用的药物有：局部OTC抗组胺药（例如ketotifen），局部处方抗组胺药（例如olopatadine，bepotastine，alcaftadine），NSAID（例如ketorolac）或肥大细胞稳定剂（例如nedocromil，cromolyn，氮卓斯汀）单独或组合使用。在我们的研究中，通过评估变应性结膜炎的四个参数（眼瘙痒，结膜充血，化学疗法和流泪）的严重程度的降低，0.7％的奥洛他汀的安全性与0.1％的奥洛他汀和0.4％的酮咯酸三甲胺的固定剂量组合相当。每天治疗超过14天。我们是从2018年8月至2019年1月进行的前瞻性病例观察性研究。从眼科门诊部筛查了80名患者。将所有符合资格标准的受试者按等比例随机分配到两个组中，即第1组（接受0.7％的奥洛他定盐酸盐滴眼液的患者）和第2组（接受0.1％的奥洛他定盐酸盐滴度+ 0.4％酮咯酸三甲胺滴眼液的患者）。 。观察到，与组2（即，联合治疗的患者）相比，组1（即，接受单药治疗的患者）的所有四个参数的降低百分比存在显着差异。由此得出的结论是，与0.1％盐酸奥洛他定+ 0.4％酮咯酸三甲胺眼液的双重联合治疗相比，发现0.7％盐酸奥洛他定眼用溶液的单药治疗更有效地减轻了过敏性结膜炎的临床体征和症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号